Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 06, 2015 4:02 AM ET

Biotechnology

Company Overview of Shantha Biotechnics Limited

Company Overview

Shantha Biotechnics Limited, a biotechnology company, researches, develops, manufactures, markets, and sells vaccines. The company offers human vaccines against hepatitis B, tetanus, diphtheria, pertussis, haemophilus influenza type B conjugate, and cholera, as well as recombinant erythropoietin. It serves customers in India and internationally. The company was founded in 1993 and is based in Hyderabad, India. Shantha Biotechnics Limited operates as a subsidiary of Sanofi Pasteur SA.

H.No 5-10-173

3rd & 4th Floor

Fateh Maidan Road

Basheerbagh

Hyderabad,  500004

India

Founded in 1993

Phone:

91 40 6630 1000

Fax:

91 40 2323 4133

Key Executives for Shantha Biotechnics Limited

Chief Executive Officer, Managing Director, Dierctor, Member of Share Transfer Committee and Member of Audit Committee
Age: 46
Founder, Chairman, Member of Share Transfer Committee, Member of Audit Committee and Member of Remuneration Committee
Age: 68
Chief Financial Officer and Company Secretary
Director, Member of Remuneration Committee, Chief Executive Officer of Sanofi Pasteur and President of Sanofi Pasteur
Age: 52
Head of Research and Development
Compensation as of Fiscal Year 2015.

Shantha Biotechnics Limited Key Developments

Shantha to Establish New Insulin Manufacturing Facility in India

Sanofi SA (France) subsidiary Shantha Biotechnics (India) announced on 29 January that it will be establishing a new insulin-production site in Telangana, India. The new facility will serve to manufacture Sanofi's human insulin product Insuman (recombinant human insulin). Sanofi has pledged an investment of INR 4.6 billion (USD 85.19 million) towards the facility and expects an annual production rate of 60 million Insuman cartridges in the first 2-3 years.

Shantha Launches Paediatric Pentavalent Vaccine, Shan5

Sanofi Pasteur launched Shan5, its paediatric pentavalent vaccine developed and manufactured by its Indian affiliate Shantha. It is a fully-liquid five-in-one vaccine that provides effective protection for children from six weeks of age against five diseases, diphtheria, tetanus, pertussis, Hib and hepatitis B. The launch of Shan5 vaccine received prequalification status from the World Health Organization (WHO) in April 2014. Shan5’s prequalification gives many more children in India access to the latest fully-liquid, 5-in-1 vaccine. Further, the prequalification helps Shan5 secure the supply of pentavalent combination vaccines in over 50 emerging and low-income countries.

Shantha Biotechnics Limited Presents at BioPharma India 2013, Nov-26-2013 11:00 AM

Shantha Biotechnics Limited Presents at BioPharma India 2013, Nov-26-2013 11:00 AM. Venue: Hyatt Regency, Mumbai, Maharashtra, India. Speakers: Dev Chandran, Head, Analytical R&D.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Shantha Biotechnics Limited, please visit www.shanthabiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.